Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%

benzinga.com/25/03/44420152/elevation-oncology-stops-early-stage-gastric-cancer-study-after-disappointing-data-lays-off-70-of-staff

On Thursday, Elevation Oncology, Inc. (NASDAQ:ELEV) elected to discontinue the development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC).
The company was developing a treatment for advanced, unresectable or metastatic gastric and gastroesophageal junction cancers.
The decision…

This story appeared on benzinga.com, 2025-03-20 15:46:32.
The Entire Business World on a Single Page. Free to Use →